Skip to content

Treatment interruption shows no benefit in HIV patients with drug resistance

New US HIV lipid guidelines favour lifestyle changes over drug therapy as first line

HAART optimism means HIV-positive IV drug users more likely to have unsafe sex and share needles

Nevirapine for PEP: should use be restricted due to liver toxicity risk?

Computer model says vaccines and treatment both needed to turn tide of HIV

Success and failure in HIV treatment: contrasting lessons from South Africa

T-20 for post-exposure prophylaxis?

Six months of DOT achieves undetectable HIV viral load in both genital tract and plasma

Initial HAART regimen lasts only 1.6 years in antiretroviral-naive